PRESS RELEASE

GLOBAL CANCER TECHNOLOGY

For Immediate Release

Contact: info@globalcancertechnology.com

GLOBAL CANCER TECHNOLOGY'S PI3K inhibitor drug shows promising preclinical results for the treatment of Glioblastoma multiforme (GBM)

GCT-007 increases CD80 expression in GBM cells

San Diego, CA, June 20, 2024—Global Cancer Technology (GCT) is pleased to announce promising new pre-clinical results for its novel and proprietary PI3 Kinase inhibitor, GCT-007. Studies conducted at the Department of Neurology at the Medical College of Wisconsin, under the direction of Dr. Ekokobe Fonkem and his team, including Dr. Charles Hay, showed that the Company's small molecule drug, GCT-007, increases the expression of CD80 in glioblastoma cells. CD80 is a well-known biomarker associated with immune response and immunotherapies.

"From previous experiments, we have seen that treatment of tumor cells with GCT-007 affects several immune inhibitory response modulators, such as PD-L1. Now we see the drug also increases CD80, a stimulatory pathway, setting up the tumor for increased immune interaction. The result suggests that GBM treatment with a combination of GCT-007 and immune therapy, such as anti-PD-1 checkpoint inhibitors, could be more powerful than either alone", said Dr. Ekokobe Fonkem, principal investigator.

John Clark, CEO of Global Cancer Technology, added, "These data are very promising, and the combined effect our drug is showing that our drug can increase the likelihood that the immune system will recognize and respond to the tumor, suggesting that treatment with GCT-007 could significantly broaden the immune response and further differentiates GCT-007 as a leading PI3K inhibitor for the treatment of GBM."

---

*Global Cancer Technology is a pre-clinical non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial {**globalcancertechnology.com**}. Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.*